Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Receivables (2022 - 2025)

Historic Receivables for Coeptis Therapeutics Holdings (COEP) over the last 4 years, with Q3 2025 value amounting to $2.2 million.

  • Coeptis Therapeutics Holdings' Receivables changed N/A to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $38978.0 for FY2023, which is 38269.97% up from last year.
  • As of Q3 2025, Coeptis Therapeutics Holdings' Receivables stood at $2.2 million.
  • Coeptis Therapeutics Holdings' Receivables' 5-year high stood at $2.2 million during Q3 2025, with a 5-year trough of $833.0 in Q3 2023.
  • Its 4-year average for Receivables is $404462.9, with a median of $38978.0 in 2023.
  • Examining YoY changes over the last 5 years, Coeptis Therapeutics Holdings' Receivables showed a top increase of 38269.97% in 2023 and a maximum decrease of 38269.97% in 2023.
  • Over the past 4 years, Coeptis Therapeutics Holdings' Receivables (Quarter) stood at $8075.0 in 2022, then soared by 382.7% to $38978.0 in 2023, then surged by 178.57% to $108581.0 in 2024, then surged by 1910.36% to $2.2 million in 2025.
  • Its Receivables stands at $2.2 million for Q3 2025, versus $30000.0 for Q2 2025 and $108581.0 for Q1 2024.